Raymond Michel Schiffelers

List of Publications by Year in Descending Order

226 papers	20,044 citations	68 h-index	139 g-index
246 ext. papers	24,771 ext. citations	8.4 avg, IF	6.79 L-index

#	Paper	IF	Citations
226	Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles.. *Journal of Controlled Release*, **2022**, 343, 207-207	11.7	4
225	Utilizing in vitro drug release assays to predict in vivo drug retention in micelles.. *International Journal of Pharmaceutics*, **2022**, 618, 121638	6.5	1
224	Extracellular vesicles enclosed-miR-421 suppresses air pollution (PM)-induced cardiac dysfunction via ACE2 signalling.. *Journal of Extracellular Vesicles*, **2022**, 11, e12222	16.4	0
223	Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. *Journal of Controlled Release*, **2021**, 341, 475-475	11.7	7
222	Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic. *Journal of Controlled Release*, **2021**, 331, 121-141	11.7	26
221	Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design. *Advanced Drug Delivery Reviews*, **2021**, 173, 252-278	18.5	19
220	A post-insertion strategy for surface functionalization of bacterial and mammalian cell-derived extracellular vesicles. *Biochimica Et Biophysica Acta - General Subjects*, **2021**, 1865, 129763	4	5
219	Natural or Synthetic RNA Delivery: A Stoichiometric Comparison of Extracellular Vesicles and Synthetic Nanoparticles. *Nano Letters*, **2021**, 21, 1888-1895	11.5	22
218	Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. *Small*, **2021**, 17, e2103025	11	5
217	Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies. *Advanced Drug Delivery Reviews*, **2021**, 175, 113801	18.5	24
216	Functional siRNA Delivery by Extracellular Vesicle-Liposome Hybrid Nanoparticles. *Advanced Healthcare Materials*, **2021**, e2101202	10.1	13
215	Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model. *International Journal of Pharmaceutics: X*, **2020**, 2, 100049	3.2	2
214	A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA. *Nature Communications*, **2020**, 11, 1113	17.4	56
213	Local release of siRNA using polyplex-loaded thermosensitive hydrogels. *Nanoscale*, **2020**, 12, 10347-10360	7.7	12
212	Potential Use of Extracellular Vesicles Generated by Microbubble-Assisted Ultrasound as Drug Nanocarriers for Cancer Treatment. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
211	Nanocarrier-based drug combination therapy for glioblastoma. *Theranostics*, **2020**, 10, 1355-1372	12.1	81
210	Repairing the heart: State-of the art delivery strategies for biological therapeutics. *Advanced Drug Delivery Reviews*, **2020**, 160, 1-18	18.5	8

209	Endothelial Cell Targeting by cRGD-Functionalized Polymeric Nanoparticles under Static and Flow Conditions. *Nanomaterials*, **2020**, 10,	5.4	7
208	Delivering the power of nanomedicine to patients today. *Journal of Controlled Release*, **2020**, 326, 164-171	11.7	101
207	Targeting the RhoGEF Trio PIX/COOL-1 in Glioblastoma: Proof of Concept Studies. *Cancers*, **2020**, 12,	6.6	1
206	The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy. *Bioconjugate Chemistry*, **2020**, 31, 2046-2059	6.3	30
205	Plasma extracellular vesicle proteins are associated with stress-induced myocardial ischemia in women presenting with chest pain. *Scientific Reports*, **2020**, 10, 12257	4.9	7
204	Dexamethasone nanomedicines for COVID-19. *Nature Nanotechnology*, **2020**, 15, 622-624	28.7	94
203	Normoxic Tumour Extracellular Vesicles Modulate the Response of Hypoxic Cancer and Stromal Cells to Doxorubicin In Vitro. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
202	Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma. *HemaSphere*, **2020**, 4, e463	0.3	2
201	Density, heterogeneity and deformability of red cells as markers of clinical severity in hereditary spherocytosis. *Haematologica*, **2020**, 105, 338-347	6.6	15
200	Extracellular vesicles as drug delivery systems: Why and how?. *Advanced Drug Delivery Reviews*, **2020**, 159, 332-343	18.5	229
199	Tumor Seeding During Colonoscopy as a Possible Cause for Metachronous Colorectal Cancer. *Gastroenterology*, **2019**, 157, 1222-1232.e4	13.3	20
198	Bacterial membrane vesicles as promising vaccine candidates. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 145, 1-6	5.7	13
197	3D-Bioprinted Mini-Brain: A Glioblastoma Model to Study Cellular Interactions and Therapeutics. *Advanced Materials*, **2019**, 31, e1806590	24	102
196	Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. *Journal of Controlled Release*, **2019**, 296, 232-240	11.7	17
195	Interfering with endolysosomal trafficking enhances release of bioactive exosomes. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 20, 102014	6	23
194	Bioprinting: 3D Bioprinting: from Benches to Translational Applications (Small 23/2019). *Small*, **2019**, 15, 1970126	11	50
193	Drug Delivery with Extracellular Vesicles: From Imagination to Innovation. *Accounts of Chemical Research*, **2019**, 52, 1761-1770	24.3	112
192	3D Bioprinting: from Benches to Translational Applications. *Small*, **2019**, 15, e1805510	11	137

191	Oligonucleotides **2019**, 305-322		2
190	Development and characterization of liposomal formulation of bortezomib. *International Journal of Pharmaceutics: X*, **2019**, 1, 100011	3.2	8
189	Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. *Experimental and Molecular Medicine*, **2019**, 51, 1-12	12.8	224
188	Routine Blood Tests Do Not Predict Survival in Patients with Glioblastoma-Multivariable Analysis of 497 Patients. *World Neurosurgery*, **2019**, 126, e1081-e1091	2.1	9
187	Cancer Modeling: 3D-Bioprinted Mini-Brain: A Glioblastoma Model to Study Cellular Interactions and Therapeutics (Adv. Mater. 14/2019). *Advanced Materials*, **2019**, 31, 1970101	24	
186	Red Blood Cells: Chasing Interactions. *Frontiers in Physiology*, **2019**, 10, 945	4.6	41
185	A head-to-head comparison of conjugation methods for VHHs: Random maleimide-thiol coupling versus controlled click chemistry. *International Journal of Pharmaceutics: X*, **2019**, 1, 100020	3.2	3
184	Anti-Inflammatory Properties of Plant Derived Natural Products - A Systematic Review. *Current Medicinal Chemistry*, **2019**, 26, 4506-4536	4.3	7
183	Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery. *Journal of Drug Targeting*, **2019**, 27, 681-689	5.4	13
182	Ultrasound-Sensitive Liposomes for Triggered Macromolecular Drug Delivery: Formulation and Characterization. *Frontiers in Pharmacology*, **2019**, 10, 1463	5.6	19
181	Biofabrication of Cell-Derived Nanovesicles: A Potential Alternative to Extracellular Vesicles for Regenerative Medicine. *Cells*, **2019**, 8,	7.9	23
180	Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach. *Nanoscale*, **2018**, 10, 2413-2426	7.7	64
179	Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovascular Research*, **2018**, 114, 19-34	9.9	198
178	State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery. *Small Methods*, **2018**, 2, 1700375	12.8	74
177	Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting. *Journal of Controlled Release*, **2018**, 282, 101-109	11.7	58
176	Squeezing for Life - Properties of Red Blood Cell Deformability. *Frontiers in Physiology*, **2018**, 9, 656	4.6	125
175	Quantitative measurement of red cell surface protein expression reveals new biomarkers for hereditary spherocytosis. *International Journal of Laboratory Hematology*, **2018**, 40, e74-e77	2.5	2
174	Polymers and hydrogels for local nucleic acid delivery. *Journal of Materials Chemistry B*, **2018**, 6, 5651-5670	7.3	22

173	Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles. *EMBO Journal*, **2018**, 37,	13	38
172	Effect of Formulation and Processing Parameters on the Size of mPEG- b-p(HPMA-Bz) Polymeric Micelles. *Langmuir*, **2018**, 34, 15495-15506	4	26
171	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*, **2018**, 7, 1535750	16.4	3642
170	The fluid membrane determines mechanics of erythrocyte extracellular vesicles and is softened in hereditary spherocytosis. *Nature Communications*, **2018**, 9, 4960	17.4	54
169	ANGI-08. TARGETING THE RhoGEF BETA-PIX TO ENHANCE THE ACTIVITY OF BEVACIZUMAB IN GLIOBLASTOMA: A NANOPARTICLE MEDIATED GENE SILENCING APPROACH. *Neuro-Oncology*, **2018**, 20, vi29-vi30	1	78
168	Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma. *International Journal of Nanomedicine*, **2018**, 13, 8105-8118	7.3	7
167	Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety. *ACS Nano*, **2018**, 12, 9815-9829	16.7	46
166	Thermosensitive liposomes for triggered release of cytotoxic proteins. *European Journal of Pharmaceutics and Biopharmaceutics*, **2018**, 132, 211-221	5.7	28
165	Nanomedicines for the treatment of hematological malignancies. *Journal of Controlled Release*, **2018**, 287, 194-215	11.7	61
164	Environmental impact of switching from the synthetic glucocorticoid prednisolone to the natural alkaloid berberine. *PLoS ONE*, **2018**, 13, e0199095	3.7	3
163	Nanomechanics of Extracellular Vesicles Reveals Vesiculation Pathways. *Small*, **2018**, 14, e1801650	11	29
162	Polyphosphate nanoparticles on the platelet surface trigger contact system activation. *Blood*, **2017**, 129, 1707-1717	2.2	86
161	Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy. *Gene Therapy*, **2017**, 24, 157-166	4	84
160	Clinical application of polymeric micelles for the treatment of cancer. *Materials Chemistry Frontiers*, **2017**, 1, 1485-1501	7.8	94
159	Obstacles and opportunities in the functional analysis of extracellular vesicle RNA - an ISEV position paper. *Journal of Extracellular Vesicles*, **2017**, 6, 1286095	16.4	410
158	Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles. *Molecular Therapy*, **2017**, 25, 1580-1587	11.7	99
157	In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System. *Molecular Pharmaceutics*, **2017**, 14, 1681-1690	5.6	12
156	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. *Journal of Controlled Release*, **2017**, 247, 127-133	11.7	69

155	Interaction of Extracellular Vesicles with Endothelial Cells Under Physiological Flow Conditions. *Methods in Molecular Biology*, **2017**, 1545, 205-213	1.4	3
154	Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis. *Journal of Controlled Release*, **2017**, 266, 100-108	11.7	208
153	Tumour-bound RNA-laden exosomes. *Nature Biomedical Engineering*, **2017**, 1, 634-636	19	10
152	Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative. *Scientific Reports*, **2017**, 7, 14322	4.9	91
151	Microbubbles-Assisted Ultrasound Triggers the Release of Extracellular Vesicles. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	21
150	Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model. *Journal of Controlled Release*, **2016**, 243, 243-249	11.7	13
149	Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e290	10.7	6
148	Extracellular vesicles for drug delivery. *Advanced Drug Delivery Reviews*, **2016**, 106, 148-156	18.5	561
147	PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. *Journal of Controlled Release*, **2016**, 224, 77-85	11.7	254
146	Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro. *PLoS ONE*, **2016**, 11, e0155325	3.7	14
145	Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment. *Pharmacological Research*, **2016**, 111, 487-500	10.2	99
144	Silencing of protease-activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice. *Haemophilia*, **2016**, 22, 152-9	3.3	4
143	Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. *Journal of Extracellular Vesicles*, **2016**, 5, 31053	16.4	190
142	Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention. *International Journal of Pharmaceutics*, **2016**, 506, 407-13	6.5	22
141	Cetuximab treatment alters the content of extracellular vesicles released from tumor cells. *Nanomedicine*, **2016**, 11, 881-90	5.6	14
140	Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via □□Stacking Stabilized Polymeric Micelles. *ACS Nano*, **2015**, 9, 3740-52	16.7	149
139	Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease. *British Journal of Haematology*, **2015**, 168, 135-8	4.5	12
138	An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs. *European Journal of Pharmaceutical Sciences*, **2015**, 74, 103-17	5.1	31

137	In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. *Cell*, **2015**, 161, 1046-1057	56.2	546
136	EVpedia: a community web portal for extracellular vesicles research. *Bioinformatics*, **2015**, 31, 933-9	7.2	256
135	Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics. *Journal of Controlled Release*, **2015**, 200, 87-96	11.7	173
134	Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. *Biomaterials*, **2014**, 35, 3365-83	15.6	588
133	Hemocompatibility assessment of two siRNA nanocarrier formulations. *Pharmaceutical Research*, **2014**, 31, 3127-35	4.5	3
132	Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. *Biomaterials*, **2014**, 35, 601-10	15.6	59
131	Intercalating quaternary nicotinamide-based poly(amido amine)s for gene delivery. *Journal of Controlled Release*, **2014**, 195, 11-20	11.7	8
130	Extracellular vesicles as drug delivery systems: lessons from the liposome field. *Journal of Controlled Release*, **2014**, 195, 72-85	11.7	287
129	Anginex lipoplexes for delivery of anti-angiogenic siRNA. *International Journal of Pharmaceutics*, **2014**, 472, 175-84	6.5	7
128	Toward routine detection of extracellular vesicles in clinical samples. *International Journal of Laboratory Hematology*, **2014**, 36, 244-53	2.5	43
127	Extracellular vesicles: potential roles in regenerative medicine. *Frontiers in Immunology*, **2014**, 5, 608	8.4	212
126	Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. *Oncotarget*, **2014**, 5, 3159-67	3.3	27
125	Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. *Oncotarget*, **2014**, 5, 6687-700	3.3	94
124	Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways. *Molecular Pharmaceutics*, **2013**, 10, 3717-27	5.6	22
123	Strategies for triggered drug release from tumor targeted liposomes. *Expert Opinion on Drug Delivery*, **2013**, 10, 1399-410	8	58
122	Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. *Journal of Controlled Release*, **2013**, 172, 229-238	11.7	333
121	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. *Journal of Controlled Release*, **2013**, 165, 110-8	11.7	72
120	Trends in polymeric delivery of nucleic acids to tumors. *Journal of Controlled Release*, **2013**, 170, 209-18	11.7	28

119	Extracellular vesicles in the circulation: are erythrocyte microvesicles a confounder in the plasma haemoglobin assay?. *Biochemical Society Transactions*, **2013**, 41, 288-92	5.1	12
118	Red blood cell vesiculation in hereditary hemolytic anemia. *Frontiers in Physiology*, **2013**, 4, 365	4.6	68
117	Taxol( )-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor( ) EL. *Nanomedicine*, **2013**, 8, 1127-35	5.6	21
116	International Society for Extracellular Vesicles: Second Annual Meeting, 17-20 April 2013, Boston, MA (ISEV 2013). *Journal of Extracellular Vesicles*, **2013**, 2, 23070	16.4	2
115	Oligonucleotides **2013**, 459-475		
114	Microparticles As Biomarkers Of Osteonecrosis Of The Hip In Sickle Cell Disease. *Blood*, **2013**, 122, 2226-2226		
113	Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin receptor. *International Journal of Pharmaceutics*, **2012**, 428, 171-7	6.5	13
112	Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. *European Journal of Pharmaceutical Sciences*, **2012**, 45, 429-35	5.1	26
111	Polyplexes based on cationic polymers with strong nucleic acid binding properties. *European Journal of Pharmaceutical Sciences*, **2012**, 45, 459-66	5.1	39
110	Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. *European Journal of Pharmaceutical Sciences*, **2012**, 45, 399-407	5.1	35
109	Attaching the phage display-selected GLA peptide to liposomes: factors influencing target binding. *European Journal of Pharmaceutical Sciences*, **2012**, 45, 330-5	5.1	20
108	Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. *Journal of Controlled Release*, **2012**, 160, 211-6	11.7	29
107	Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines. *Journal of Controlled Release*, **2012**, 160, 232-8	11.7	19
106	Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. *Journal of Controlled Release*, **2012**, 161, 635-44	11.7	290
105	Drug targeting systems for inflammatory disease: one for all, all for one. *Journal of Controlled Release*, **2012**, 161, 225-34	11.7	79
104	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. *Journal of Controlled Release*, **2012**, 159, 281-9	11.7	69
103	MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. *Journal of Controlled Release*, **2012**, 161, 772-80	11.7	46
102	Physicochemical and biological evaluation of siRNA polyplexes based on PEGylated Poly(amido amine)s. *Pharmaceutical Research*, **2012**, 29, 352-61	4.5	65

101	Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression. *Pharmaceutical Research*, **2012**, 29, 669-82	4.5	35
100	Exosome mimetics: a novel class of drug delivery systems. *International Journal of Nanomedicine*, **2012**, 7, 1525-41	7.3	258
99	Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles. *Journal of Controlled Release*, **2012**, 163, 361-7	11.7	38
98	Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. *International Journal of Nanomedicine*, **2012**, 7, 467-82	7.3	25
97	Micro-Vesiculation and Disease, London, 13-14 September 2012. *Journal of Extracellular Vesicles*, **2012**, 1, 19768	16.4	1
96	Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis. *Angewandte Chemie*, **2012**, 124, 7366-7370	3.6	9
95	Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. *Angewandte Chemie - International Edition*, **2012**, 51, 7254-8	16.4	87
94	Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. *PLoS Biology*, **2012**, 10, e1001450	9.7	800
93	Polymeric carrier systems for siRNA delivery. *Current Topics in Medicinal Chemistry*, **2012**, 12, 108-19	3	19
92	A role for activated endothelial cells in red blood cell clearance: implications for vasopathology. *Haematologica*, **2012**, 97, 500-8	6.6	48
91	Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. *Journal of Extracellular Vesicles*, **2012**, 1,	16.4	392
90	Gene silencing activity of siRNA polyplexes based on biodegradable polymers. *European Journal of Pharmaceutics and Biopharmaceutics*, **2011**, 77, 450-7	5.7	32
89	Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. *Anti-Cancer Drugs*, **2011**, 22, 223-33	2.4	69
88	A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy. *International Journal of Nanomedicine*, **2011**, 6, 2697-703	7.3	21
87	Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. *Journal of Controlled Release*, **2011**, 150, 30-6	11.7	141
86	Optimization of poly(amido amine)s as vectors for siRNA delivery. *Journal of Controlled Release*, **2011**, 150, 177-86	11.7	44
85	Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. *Journal of Controlled Release*, **2011**, 151, 10-7	11.7	50
84	Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes. *Journal of Controlled Release*, **2011**, 155, 282-8	11.7	84

83	Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors. *International Journal of Pharmaceutics*, **2011**, 416, 448-52	6.5	6
82	Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. *International Journal of Pharmaceutics*, **2011**, 416, 433-42	6.5	223
81	SiRNA delivery with functionalized carbon nanotubes. *International Journal of Pharmaceutics*, **2011**, 416, 419-25	6.5	99
80	The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. *Drug Discovery Today*, **2011**, 16, 219-28	8.8	56
79	In vivo methods to study uptake of nanoparticles into the brain. *Pharmaceutical Research*, **2011**, 28, 456-71	4.5	98
78	Disulfide-based poly(amido amine)s for siRNA delivery: effects of structure on siRNA complexation, cellular uptake, gene silencing and toxicity. *Pharmaceutical Research*, **2011**, 28, 1013-22	4.5	42
77	Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. *Angiogenesis*, **2011**, 14, 143-53	10.6	10
76	Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. *Angiogenesis*, **2011**, 14, 457-66	10.6	36
75	Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals. *BioDrugs*, **2011**, 25, 171-89	7.9	1
74	Liposomes targeting tumour stromal cells. *Molecular Membrane Biology*, **2010**, 27, 328-40	3.4	5
73	Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. *Molecular Pharmaceutics*, **2010**, 7, 2020-9	5.6	128
72	Gene silencing activity of siRNA polyplexes based on thiolated N,N,N-trimethylated chitosan. *Bioconjugate Chemistry*, **2010**, 21, 2339-46	6.3	55
71	Tumor vasculature as target for therapeutic intervention. *Expert Opinion on Investigational Drugs*, **2010**, 19, 1321-38	5.9	16
70	Identification of peptide ligands for targeting to the blood-brain barrier. *Pharmaceutical Research*, **2010**, 27, 673-82	4.5	50
69	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. *Journal of Controlled Release*, **2010**, 145, 165-75	11.7	99
68	A method for quantifying cellular uptake of fluorescently labeled siRNA. *Journal of Controlled Release*, **2010**, 148, 106-109	11.7	30
67	Poly(amido amine) copolymers derived from aminobutanol and ethylene diamine are excellent carriers for siRNA delivery. *Journal of Controlled Release*, **2010**, 148, e85-6	11.7	1
66	Photochemical internalization (PCI)-mediated enhancement of gene silencing efficiency of polymethacrylates and N,N,N-trimethylated chitosan (TMC) based siRNA polyplexes. *Journal of Controlled Release*, **2010**, 148, e98-9	11.7	9

65	Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. *Journal of Controlled Release*, **2010**, 148, 303-10	11.7	45
64	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. *Drug Discovery Today*, **2010**, 15, 102-14	8.8	41
63	Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability. *Experimental Hematology*, **2010**, 38, 282-91	3.1	19
62	Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. *Biomaterials*, **2010**, 31, 7797-804	15.6	218
61	Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. *Current Cancer Drug Targets*, **2009**, 9, 748-60	2.8	140
60	Targeted delivery of anti-inflammatory agents to tumors. *Current Pharmaceutical Design*, **2009**, 15, 1825-43	3.3	12
59	Drug Delivery--Select Biosciences Inaugural Summit. 2-4 September 2009, London, UK. *IDrugs: the Investigational Drugs Journal*, **2009**, 12, 679-82		1
58	Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. *British Journal of Cancer*, **2008**, 99, 1256-64	8.7	26
57	Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. *Journal of Controlled Release*, **2008**, 127, 131-6	11.7	33
56	Utility of targeted glucocorticoids in cancer therapy. *Journal of Liposome Research*, **2008**, 18, 47-57	6.1	18
55	Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. *Neoplasia*, **2008**, 10, 108-17	6.4	73
54	Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. *Journal of Steroid Biochemistry and Molecular Biology*, **2008**, 111, 101-10	5.1	49
53	Therapeutic nanomedicine: Liposomal corticosteroid as targeted antiinflammatory nanomedicine. *European Journal of Nanomedicine*, **2008**, 1,		1
52	Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells. *Blood*, **2008**, 111, 4542-50	2.2	55
51	Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo. *Current Pharmaceutical Design*, **2008**, 14, 3686-97	3.3	37
50	Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil. *Pharmaceutical Research*, **2008**, 25, 1948-55	4.5	30
49	Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. *International Journal of Pharmaceutics*, **2008**, 364, 258-64	6.5	27
48	Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. *International Journal of Pharmaceutics*, **2007**, 331, 167-75	6.5	96

47	Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. *International Journal of Pharmaceutics*, **2007**, 331, 211-4	6.5	127
46	Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. *Biomaterials*, **2007**, 28, 5581-93	15.6	237
45	Synthetic delivery systems for intravenous administration of nucleic acids. *Nanomedicine*, **2007**, 2, 169-81	5.6	10
44	Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. *Journal of Antimicrobial Chemotherapy*, **2007**, 60, 1064-73	5.1	24
43	Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. *Biochimica Et Biophysica Acta - Biomembranes*, **2007**, 1768, 1211-7	3.8	80
42	Targeting the retinal microcirculation to treat diabetic sight problems. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 1493-502	6.4	6
41	Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. *Journal of Controlled Release*, **2006**, 113, 1-8	11.7	57
40	Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. *Arthritis and Rheumatism*, **2006**, 54, 1198-208		150
39	Targeted delivery of siRNA. *Journal of Biomedicine and Biotechnology*, **2006**, 2006, 63675		51
38	Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. *Journal of Liposome Research*, **2006**, 16, 185-94	6.1	48
37	Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. *Expert Opinion on Biological Therapy*, **2006**, 6, 605-17	5.4	47
36	ICS-283: a system for targeted intravenous delivery of siRNA. *Expert Opinion on Drug Delivery*, **2006**, 3, 445-54	8	17
35	Silencing Proteins: Nanotechnological Approaches to Deliver siRNA for Cancer Therapy **2006**, 127-153		
34	Pharmaceutical Nanocarriers in Treatment and Imaging of Infection **2006**, 697-711		1
33	Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. *Neoplasia*, **2005**, 7, 118-27	6.4	84
32	RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. *Drug Resistance Updates*, **2005**, 8, 381-402	23.2	371
31	Long-circulating sterically stabilized liposomes in the treatment of infections. *Methods in Enzymology*, **2005**, 391, 228-60	1.7	32
30	siRNA as a new drug: intellectual property. *Expert Opinion on Therapeutic Patents*, **2005**, 15, 141-152	6.8	1

29	Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. *Journal of Controlled Release*, **2005**, 103, 341-53	11.7	262
28	Transporting silence: design of carriers for siRNA to angiogenic endothelium. *Journal of Controlled Release*, **2005**, 109, 5-14	11.7	34
27	Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. *Arthritis and Rheumatism*, **2005**, 52, 1314-8		125
26	siRNA-mediated inhibition of angiogenesis. *Expert Opinion on Biological Therapy*, **2005**, 5, 359-68	5.4	8
25	Liposomal targeting of angiogenic vasculature. *Current Drug Delivery*, **2005**, 2, 363-8	3.2	10
24	Pharmaceutical prospects for RNA interference. *Pharmaceutical Research*, **2004**, 21, 1-7	4.5	62
23	Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. *Nucleic Acids Research*, **2004**, 32, e149	20.1	706
22	Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. *American Journal of Pathology*, **2004**, 165, 2177-85	5.8	205
21	Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. *Journal of Controlled Release*, **2003**, 91, 115-22	11.7	274
20	Peptide-targeted PEG-liposomes in anti-angiogenic therapy. *International Journal of Pharmaceutics*, **2003**, 254, 55-8	6.5	73
19	Innovations in liposomal formulations for antimicrobial therapy. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 1127-1140	6.8	3
18	Liposome-enabled synergistic interaction of antimicrobial agents. *Journal of Liposome Research*, **2002**, 12, 121-7	6.1	6
17	Endothelial cells at inflammatory sites as target for therapeutic intervention. *Endothelium: Journal of Endothelial Cell Research*, **2002**, 9, 161-71		43
16	Ligand-targeted liposomes directed against pathological vasculature. *Journal of Liposome Research*, **2002**, 12, 129-35	6.1	14
15	Biodistribution of long-circulating PEG-liposomes in a murine model of established subcutaneous abscesses. *Biochimica Et Biophysica Acta - Biomembranes*, **2002**, 1561, 91-7	3.8	9
14	Activity of mammalian secreted phospholipase A(2) from inflammatory peritoneal fluid towards PEG-liposomes. Early indications. *International Journal of Pharmaceutics*, **2001**, 214, 93-8	6.5	7
13	Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. *International Journal of Pharmaceutics*, **2001**, 214, 103-5	6.5	10
12	Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. *Pharmaceutical Research*, **2001**, 18, 780-7	4.5	42

11	Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 464-70	5.9	25
10	Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. *Journal of Antimicrobial Chemotherapy*, **2001**, 48, 333-44	5.1	117
9	Targeting of Antibiotics in Bacterial Infections Using Pegylated Long-Circulating Liposomes. *Journal of Liposome Research*, **2000**, 10, 513-521	6.1	7
8	Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. *Biochimica Et Biophysica Acta - Biomembranes*, **2000**, 1468, 253-61	3.8	34
7	Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. *Biochimica Et Biophysica Acta - Biomembranes*, **1999**, 1421, 329-39	3.8	47
6	Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice. *Atherosclerosis*, **1998**, 141, 237-47	3.1	15
5	Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. *Molecular Pharmacology*, **1997**, 52, 445-55	4.3	44
4	Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1996**, 16, 926-33	9.4	69
3	Lipid-Based Formulations for siRNA Delivery291-304		1
2	EVQuant; high-throughput quantification and characterization of extracellular vesicle (sub)populations		3
1	The Fluid Membrane determines Mechanics of Red Blood Cell Extracellular Vesicles and is Softened in Hereditary Spherocytosis		1